Logo image of PROF

PROFOUND MEDICAL CORP (PROF) Stock Fundamental Analysis

NASDAQ:PROF - Nasdaq - CA74319B5027 - Common Stock - Currency: USD

5.57  -0.09 (-1.59%)

Fundamental Rating

4

Taking everything into account, PROF scores 4 out of 10 in our fundamental rating. PROF was compared to 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of PROF is average, but there are quite some concerns on its profitability. PROF shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PROF has reported negative net income.
In the past year PROF has reported a negative cash flow from operations.
In the past 5 years PROF always reported negative net income.
PROF had a negative operating cash flow in each of the past 5 years.
PROF Yearly Net Income VS EBIT VS OCF VS FCFPROF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

PROF has a worse Return On Assets (-52.50%) than 67.55% of its industry peers.
PROF has a Return On Equity (-62.92%) which is in line with its industry peers.
Industry RankSector Rank
ROA -52.5%
ROE -62.92%
ROIC N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
PROF Yearly ROA, ROE, ROICPROF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With a decent Gross Margin value of 67.64%, PROF is doing good in the industry, outperforming 75.53% of the companies in the same industry.
In the last couple of years the Gross Margin of PROF has grown nicely.
The Profit Margin and Operating Margin are not available for PROF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
PROF Yearly Profit, Operating, Gross MarginsPROF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PROF has been increased compared to 1 year ago.
The number of shares outstanding for PROF has been increased compared to 5 years ago.
Compared to 1 year ago, PROF has an improved debt to assets ratio.
PROF Yearly Shares OutstandingPROF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PROF Yearly Total Debt VS Total AssetsPROF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 3.54 indicates that PROF is not in any danger for bankruptcy at the moment.
PROF has a Altman-Z score of 3.54. This is in the better half of the industry: PROF outperforms 72.87% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that PROF is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.09, PROF is doing good in the industry, outperforming 60.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.54
ROIC/WACCN/A
WACC7.61%
PROF Yearly LT Debt VS Equity VS FCFPROF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

PROF has a Current Ratio of 11.31. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 11.31, PROF belongs to the best of the industry, outperforming 93.62% of the companies in the same industry.
PROF has a Quick Ratio of 10.03. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.03, PROF belongs to the top of the industry, outperforming 93.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.31
Quick Ratio 10.03
PROF Yearly Current Assets VS Current LiabilitesPROF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

PROF shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.43%.
Looking at the last year, PROF shows a very strong growth in Revenue. The Revenue has grown by 63.64%.
PROF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.67% yearly.
EPS 1Y (TTM)5.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.46%
Revenue 1Y (TTM)63.64%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%37.23%

3.2 Future

Based on estimates for the next years, PROF will show a very strong growth in Earnings Per Share. The EPS will grow by 36.68% on average per year.
Based on estimates for the next years, PROF will show a very strong growth in Revenue. The Revenue will grow by 78.52% on average per year.
EPS Next Y-0.1%
EPS Next 2Y10.45%
EPS Next 3Y-0.93%
EPS Next 5Y36.68%
Revenue Next Year62.2%
Revenue Next 2Y94.92%
Revenue Next 3Y72.92%
Revenue Next 5Y78.52%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PROF Yearly Revenue VS EstimatesPROF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PROF Yearly EPS VS EstimatesPROF Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PROF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PROF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROF Price Earnings VS Forward Price EarningsPROF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROF Per share dataPROF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.45%
EPS Next 3Y-0.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PROF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROFOUND MEDICAL CORP

NASDAQ:PROF (6/6/2025, 8:20:43 PM)

5.57

-0.09 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners50.32%
Inst Owner Change-6.34%
Ins Owners7.71%
Ins Owner Change3.75%
Market Cap167.38M
Analysts83.33
Price Target17.56 (215.26%)
Short Float %1.93%
Short Ratio5.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.79%
Min EPS beat(2)-27.3%
Max EPS beat(2)42.88%
EPS beat(4)2
Avg EPS beat(4)-2%
Min EPS beat(4)-28.63%
Max EPS beat(4)42.88%
EPS beat(8)5
Avg EPS beat(8)-0.74%
EPS beat(12)8
Avg EPS beat(12)3.97%
EPS beat(16)9
Avg EPS beat(16)-0.83%
Revenue beat(2)0
Avg Revenue beat(2)-14.46%
Min Revenue beat(2)-25.86%
Max Revenue beat(2)-3.06%
Revenue beat(4)0
Avg Revenue beat(4)-9.8%
Min Revenue beat(4)-25.86%
Max Revenue beat(4)-2.68%
Revenue beat(8)1
Avg Revenue beat(8)-14.23%
Revenue beat(12)2
Avg Revenue beat(12)-15.45%
Revenue beat(16)3
Avg Revenue beat(16)-18.87%
PT rev (1m)0%
PT rev (3m)19.42%
EPS NQ rev (1m)-19.05%
EPS NQ rev (3m)-25.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.68%
Revenue NQ rev (1m)-1.64%
Revenue NQ rev (3m)-36.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-35.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.11
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 3.31
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.39
BVpS1.69
TBVpS1.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.5%
ROE -62.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.64%
FCFM N/A
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.31
Quick Ratio 10.03
Altman-Z 3.54
F-Score4
WACC7.61%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.46%
EPS Next Y-0.1%
EPS Next 2Y10.45%
EPS Next 3Y-0.93%
EPS Next 5Y36.68%
Revenue 1Y (TTM)63.64%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%37.23%
Revenue Next Year62.2%
Revenue Next 2Y94.92%
Revenue Next 3Y72.92%
Revenue Next 5Y78.52%
EBIT growth 1Y-24.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.29%
EBIT Next 3Y18.96%
EBIT Next 5Y39.35%
FCF growth 1Y-12.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.09%
OCF growth 3YN/A
OCF growth 5YN/A